Exchange: NASDAQ Sector: Healthcare Industry: Diagnostics & Research
0.22% $0.455
America/New_York / 27 apr 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 16.71 mill |
EPS: | -0.720 |
P/E: | -0.632 |
Earnings Date: | Aug 02, 2023 |
SharesOutstanding: | 36.73 mill |
Avg Daily Volume: | 0.538 mill |
RATING 2023-04-27 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.632 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.03x |
Company: PE -0.632 | industry: PE 18.71 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.430 - 0.480 ( +/- 5.49%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-11 | Angelico Paul | Buy | 29 333 | Common Stock |
2023-03-15 | Angelico Paul | Buy | 7 885 | Common Stock |
2023-03-15 | Angelico Paul | Sell | 2 843 | Common Stock |
2023-03-11 | Angelico Paul | Sell | 10 575 | Common Stock |
2023-03-11 | Angelico Paul | Sell | 29 333 | Restricted stock units |
INSIDER POWER |
---|
-90.26 |
Last 100 transactions |
Buy: 781 277 | Sell: 10 790 554 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.455 (0.22% ) |
Volume | 0.352 mill |
Avg. Vol. | 0.538 mill |
% of Avg. Vol | 65.31 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases. The company sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, and DPP trademarks, as well as sells its products directly through distributors to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. It has collaboration agreements with Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, The Oswaldo Cruz Foundation, and the Foundation for Innovative New Diagnostics, as well as U.S. government agencies, such as Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.